Literature DB >> 12589521

EEG effects of buspirone and pindolol: a method of examining 5-HT1A receptor function in humans.

R H McAllister-Williams1, A E Massey.   

Abstract

RATIONALE: An involvement of 5-HT(1A) receptors is postulated in the pathophysiology of affective disorders and mechanism of action of antidepressants. Methods for studying their functional integrity in humans are, however, limited. Preliminary data suggests that activation of somatodendritic 5-HT(1A) receptors cause a negative shift in the EEG frequency spectrum. Animal research suggests that pindolol is an agonist at these receptors but an antagonist at postsynaptic 5-HT(1A) receptors.
OBJECTIVE: We postulated that while pindolol would antagonise known postsynaptic mediated neuroendocrine responses to the 5-HT(1A) agonist buspirone, both drugs would have a similar effect on the EEG frequency spectrum.
METHODS: Fourteen healthy men were administered placebo or pindolol (20 mg orally) 90 min before placebo or buspirone (30 mg orally) in a double blind cross-over study. Plasma prolactin and growth hormone were assayed and EEGs recorded before and after drug administration.
RESULTS: A significant negative shift in the EEG frequency spectrum was found for both buspirone and pindolol, with the combination producing a similar effect to each drug alone. In contrast, the neuroendocrine response to buspirone was significantly attenuated by pindolol.
CONCLUSIONS: The data obtained are consistent with the EEG effects of buspirone and pindolol being mediated by somatodendritic 5-HT(1A) receptors, in contrast to the neuroendocrine response, which is known to be mediated by postsynaptic receptors. The development of this novel method of assessing somatodendritic 5-HT(1A) receptors in humans is a potentially important advance which may allow the testing of hypotheses of its involvement in depression and response to antidepressants.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12589521     DOI: 10.1007/s00213-002-1339-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  49 in total

1.  A solution for reliable and valid reduction of ocular artifacts, applied to the P300 ERP.

Authors:  H V Semlitsch; P Anderer; P Schuster; O Presslich
Journal:  Psychophysiology       Date:  1986-11       Impact factor: 4.016

2.  Restriction to a limited set of EEG-target variables may lead to misinterpretation of pharmaco-EEG results.

Authors:  P Anderer; M J Barbanoj; B Saletu; H V Semlitsch
Journal:  Neuropsychobiology       Date:  1993       Impact factor: 2.328

3.  Effect of pindolol on hormone secretion and body temperature: partial agonist effects.

Authors:  H Y Meltzer; M Maes
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Antagonist properties of (-)-pindolol and WAY 100635 at somatodendritic and postsynaptic 5-HT1A receptors in the rat brain.

Authors:  R Corradetti; N Laaris; N Hanoun; A M Laporte; E Le Poul; M Hamon; L Lanfumey
Journal:  Br J Pharmacol       Date:  1998-02       Impact factor: 8.739

5.  Comparative anatomical distribution of serotonin 1A, 1D alpha and 2A receptor mRNAs in human brain postmortem.

Authors:  M Pasqualetti; I Nardi; H Ladinsky; D Marazziti; G B Cassano
Journal:  Brain Res Mol Brain Res       Date:  1996-07

6.  Inhibition of REM sleep by ipsapirone, a 5HT1A agonist, in normal volunteers.

Authors:  J C Gillin; W Jernajczyk; D C Valladares-Neto; S Golshan; M Lardon; S M Stahl
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

7.  Effects of hydrocortisone on brain 5-HT function and sleep.

Authors:  A H Young; A L Sharpley; G M Campling; R A Hockney; P J Cowen
Journal:  J Affect Disord       Date:  1994-10       Impact factor: 4.839

8.  Blunted growth hormone and prolactin responses to L-tryptophan in depression; a state-dependent abnormality.

Authors:  A K Upadhyaya; I Pennell; P J Cowen; J F Deakin
Journal:  J Affect Disord       Date:  1991-03       Impact factor: 4.839

9.  Characteristics of the anxiolytic effects of buspirone in high- and low-anxious normal humans assessed by frontal midline theta activity.

Authors:  Y Mizuki; M Suetsugi; I Ushijima; M Yamada
Journal:  Methods Find Exp Clin Pharmacol       Date:  1994-05

10.  The flesinoxan 5-HT1A receptor challenge in major depression and suicidal behavior.

Authors:  W Pitchot; M Ansseau; A Gonzalez Moreno; M Lembreghts; M Hansenne; J Wauthy; C Reel; R Jammaer; P Papart; J Sulon
Journal:  Pharmacopsychiatry       Date:  1995-10       Impact factor: 5.788

View more
  5 in total

1.  Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment.

Authors:  M M Jukić; N Opel; J Ström; T Carrillo-Roa; S Miksys; M Novalen; A Renblom; S C Sim; E M Peñas-Lledó; P Courtet; A Llerena; B T Baune; D J de Quervain; A Papassotiropoulos; R F Tyndale; E B Binder; U Dannlowski; M Ingelman-Sundberg
Journal:  Mol Psychiatry       Date:  2016-11-29       Impact factor: 15.992

Review 2.  5-HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function.

Authors:  Alvaro L Garcia-Garcia; Adrian Newman-Tancredi; E David Leonardo
Journal:  Psychopharmacology (Berl)       Date:  2013-12-12       Impact factor: 4.530

Review 3.  Corticosteroid-serotonin interactions in depression: a review of the human evidence.

Authors:  Richard J Porter; Peter Gallagher; Stuart Watson; Allan H Young
Journal:  Psychopharmacology (Berl)       Date:  2004-03-09       Impact factor: 4.530

4.  Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man.

Authors:  Klaas P Zuideveld; Piet H Van der Graaf; Lambertus A Peletier; Meindert Danhof
Journal:  Pharm Res       Date:  2007-05-31       Impact factor: 4.200

5.  Serotonin Neuronal Function from the Bed to the Bench: Is This Really a Mirrored Way?

Authors:  Adeline Etievant; Thorsten Lau; Guillaume Lucas; Nasser Haddjeri
Journal:  eNeuro       Date:  2019-06-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.